SCHEMBL12716617

SCHEMBL12716617

c1ccc(-n2c3cc(-c4cc5cccc6ccc7cccc4c7c65)ccc3c3ccc(-c4cc5cccc6ccc7cccc4c7c65)cc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
ERBB2 P04626 1/20 0.45
FYN P06241 1/20 0.45
MAOA P21397 1/20 0.45
ACHE P22303 1/20 0.45
AHR P35869 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.42
KDM4E B2RXH2 1/20 0.42
ATM Q13315 1/20 0.42
ALDH1A1 P00352 7/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 4/20 0.37
THRB P10828 1/20 0.37
TSHR P16473 4/20 0.33
CYP3A4 P08684 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAPK1 P28482 2/20 0.32
CASP1 P29466 2/20 0.32
HIF1A Q16665 2/20 0.32
MEN1 O00255 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23109469 0.92 L3MBTL1 (0.41) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL12716557 0.90 L3MBTL1 (0.49) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL17692115 0.89 KDM4E (0.47) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL27365680 0.89 L3MBTL1 (0.47) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL12716586 0.89 ALDH1A1 (0.37) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL12716616 0.88 L3MBTL1 (0.39) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL27366191 0.88 L3MBTL1 (0.49) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL15446753 0.87 KDM4E (0.45) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL22706775 0.87 KDM4E (0.40) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL21190610 0.86 L3MBTL1 (0.37) CYP1A2ERBB2FYNMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923129-B2 extremely high efficiency and a high luminance and has an extremely high durability; 2-pyrenylcarbazoles; blue CANON KABUSHIKI KAISHA (JP) 2011-04-12 US disclosed
US-7923129-B2 extremely high efficiency and a high luminance and has an extremely high durability; 2-pyrenylcarbazoles; blue CANON KABUSHIKI KAISHA (JP) 2011-04-12 US disclosed
US-20080131731-A1 CARBAZOLE DERIVATIVE AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2008-06-05 US disclosed
US-20080131731-A1 CARBAZOLE DERIVATIVE AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131731-A1 CARBAZOLE DERIVATIVE AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME OXA1L, CYP2C19, PPOX CYP1A2 18/4885ERBB2 3354/4885FYN 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.